Clinical trial
Dosage Schedule Study of Pemetrexed Monochemotherapy for Locally Advanced or…
NCT00370292 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00370292 |
|---|---|
| Title | Dosage Schedule Study of Pemetrexed Monochemotherapy for Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) |
| Official title | Pemetrexed Monochemotherapy in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer. A Pilot Study to Define the Best Dosing Schedule for a Planned Phase II Randomized Trial |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Non Small Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | Pemetrexed - Before Protocol Amendment, Pemetrexed - After Protocol Amendment |
| Enrollment | 19 |
| Start date | Sep 1, 2006 |
| Primary completion | Sep 1, 2008 |
| Completion | Sep 1, 2008 |
| First posted | Aug 31, 2006 |
| Last update posted | Oct 20, 2009 |
| Countries | Italy |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: